

Association for Molecular Pathology Candidate Biosketch

Name, Degree: Timothy J. O'Leary, M.D., Ph.D.

Current Position: Director, Biomedical Laboratory R&D Service
Director, Clinical Science R&D Service
Acting Deputy Chief R&D Officer
Veterans Health Administration

Institution: Department of Veterans Affairs
Washington, DC 20420

Degree(s): M.D. University of Michigan, 1979
Ph.D., Stanford University, 1976

Residency and/or Fellowship Training: Residency and Fellowship in Anatomic Pathology,
National Cancer Institute, 1979-1982.

Prior Experience:

Research Associate, Department of Physiology, University of Michigan 1977-79
Medical Staff Fellow, Laboratory of Chemical Physics, National Institute of Diabetes and
Digestive and Kidney Diseases, 1982-1986
Senior Staff Fellow, Office of Biologics Review and Evaluation, FDA, 1986-1987
Chairman, Department of Cellular Pathology and Genetics, Armed Forces Institute of
Pathology, 1987-2004
Director, Division of Immunology and Hematology, FDA, 2003 (on leave from AFIP)

Board Certifications: American Board of Pathology, Anatomic Pathology, 1982
American Board of Pathology and American Board of Medical Genetics,
Molecular Genetic Pathology, 2002

AMP Involvement: AMP Member since: 1996 AMP Offices & Committees:

Chair, Hematopathology Section, 1998
Member, Clinical Practice Committee, 2000-2001
Member, Professional Relationships Committee, 2002
Member, Nominating Committee, 2006-2007
Faculty, MGB Board Review Course, 2007
Program Chair-Elect, 2008
Program Chair, 2009

Membership & Activities in Other Professional Societies:

United States - Canadian Academy of Pathology, American College of Medical Genetics
(Affiliate), College of American Pathologists, American Society of Cytology, American Physical
Society, Biophysical Society
Member, Department of Defense Process Action Team for Clinical Genetics, 1995-1996.
Chair, Hematology and Pathology Devices Panel, Medical Devices Advisory Committee,
Center for Devices and Radiologic Health, Food and Drug Administration, 1996-2000.
Member, Department of Health and Human Services Clinical Laboratory Improvement Advisory
Committee, 1999-2003.
National Advisory General Medical Sciences Council, National Institutes of Health, 2006-
2009 (*ex officio*).

Member , Area Committee on Molecular Methods, National Committee for Clinical Laboratory Standards (now CLSI), 1993-2006.
Vice Chairholder, Area Committee on Molecular Methods, National Committee for Clinical Laboratory Standards, 1993-1998.
Chairholder, Subcommittee on Molecular Hematology, National Committee for Clinical Laboratory Standards, 1993-2002
Chairholder, Subcommittee on Immunohistochemistry, National Committee for Clinical Laboratory Standards, 1995-1999.
Board of Directors, Clinical Laboratory Standards Institute (formerly NCCLS), 2007-
Member, Molecular Pathology Testing Committee, American Board of Pathology, 1997-1999.
Member, Molecular Genetic Pathology Test Committee, American Board of Pathology and American Board of Medical Genetics, 2000-2002.
Editorial Board, Human Pathology, 2001-present.
Editorial Board, Pathology Research and Practice, 1992-present.
Editorial Board, Applied Immunohistochemistry and Molecular Morphology, 1999-present.
Board of Directors, Armed Forces Institute of Regenerative Medicine, 2009-present

Candidate's Personal Statement: The Association of Molecular Pathology has become the premier organization for bringing together under one umbrella those who use molecular diagnostics in genetics, infectious diseases, and anatomic pathology. AMP and its members have both created a new field of specialization, high standards for its practice and, through the Annual Meeting and the Journal of Molecular Diagnostics, an educational program to help us live up to those high standards. It has been one of the great pleasures of my life to work with AMP and its many wonderful people since almost the beginning of the organization, and it would be a privilege to work with the membership to increase the already high professional competence of our members, the confidence of the lay public and government in the quality of molecular testing performed by AMP members, access to molecular testing through appropriate reimbursement policies and non-exclusive access to intellectual property, and awareness of the importance of molecular testing through outreach programs.